News

Ideas That Generate Results

Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023

Mar 28, 2018

Share |
Antibody Drug Conjugates are the fastest growing class of oncology therapeutics. These are monoclonal antibody based therapies which have achieved great success in the field of cancer treatment, primarily when used with cytotoxic drugs. ADC is a class of therapeutics which harnesses the antigen-selectivity of monoclonal antibodies to deliver the highly potent cytotoxic drugs to antigen expressing tumor cells. The use of monoclonal antibody directed delivery confers a therapeutic index to highly potent cytotoxic drugs, increasing both the efficacy and safety of therapy. Such novel anti-cancer drugs are being used these days to target cancers, while minimizing the exposure of healthy tissue. The recent approval of four ADCs in the global market and a strong pipeline of such drugs, highlight the potential for new therapeutic innovations in this industry.
 
According to the RNCOS report entitled “Global Antibody Drug Conjugate Drug Sales, Pipeline Analysis (By Phase, Linker, Technology, and Indication) & Market Forecast to 2023”, the Global Antibody Drug Conjugates Market is anticipated to witness a double digit growth during 2017-2023. The report provides information about the current and future market scenario of the Global ADCs Market. The report also highlights the major drivers, such as increasing incidences of cancer and advances in linking technologies, for the Global Antibody Drug Conjugates Market. Furthermore, the report also gives information related to the commercially available ADCs such as ADCETRIS, Kadcyla, Mylotarg and Besponsa.
 
Moreover, few hindrances, such as high cost of production cost, lack of experienced manufacturers and regulatory challenges, which are slowing down the growth of the Global ADCs Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.
 
As per RNCOS latest research reports, the information regarding ADCs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies has been highlighted. The pipeline chapter provides in depth analysis of ADCs of companies as well as research organizations by clinical phase, indications for which they are being developed, type of linker, drugs, and technology. Additionally, the study provides all-inclusive current analysis of various ADCs in advanced as well as early stages of development. Moreover, our report places an emphasis on the strategic alliances that can impact industry’s growth.
 
The prominent players in Global Antibody Drug Conjugates Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Global Antibody Drug Conjugates Market.
 
RNCOS has over a decade of experience in Healthcare Market Reports. We can act as a potential growth partner in all your business endeavours, such as product launching, geographic expansion, sales improvement, distributor/retailer tie-ups etc. Furthermore, RNCOS can help make your business flourish by studying the market dynamics and devising the right strategies.
 
Feel free to download the latest sample: Global Antibody Drug Conjugate Drug Sales Market


Media Citation

get in touch

Please fill-in the information below.